Table 1.
Characteristics of the participants in this study (n = 83)
| Male | Female | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sarcopenia (n = 26) | Pre‐sarcopenia (n = 12) | Non‐sarcopenia (n = 12) | P value (sarcopenia vs. non‐sarcopenia) | P value (sarcopenia vs. pre‐sarcopenia) | P value (pre‐sarcopenia vs. non‐sarcopenia) | Sarcopenia (n = 22) | Pre‐sarcopenia (n = 4) | Non‐sarcopenia (n = 7) | P value (sarcopenia vs. non‐sarcopenia) | P value (sarcopenia vs. pre‐sarcopenia) | P value (pre‐sarcopenia vs. non‐sarcopenia) | |
| Age (years) | 78.5 ± 1.4 | 73.8 ± 2.0 | 71.3 ± 1.6 | 0.01 | 0.13 | 0.65 | 79.1 ± 1.5 | 74.3 ± 4.1 | 77.7 ± 1.6 | 0.88 | 0.40 | 0.71 |
| Time on haemodialysis (years) | 9.0 ± 1.8 | 2.9 ± 0.8 | 2.7 ± 0.5 | 0.04 | 0.05 | 1.00 | 11.6 ± 3.9 | 9.5 ± 2.6 | 8.0 ± 2.1 | 0.86 | 0.97 | 0.99 |
| Body weight (kg) | 55.2 ± 1.9 | 62.1 ± 2.7 | 65.7 ± 2.0 | 0.006 | 0.09 | 0.62 | 44.5 ± 1.8 | 51.9 ± 1.0 | 56.0 ± 3.1 | 0.009 | 0.25 | 0.70 |
| Body mass index(kg/m2) | 21.7 ± 0.6 | 23.3 ± 0.8 | 23.9 ± 0.6 | 0.08 | 0.27 | 0.85 | 19.8 ± 0.6 | 24.0 ± 1.4 | 23.8 ± 1.3 | 0.03 | 0.07 | 1.00 |
| Skeletal mass index (kg/m2) | 6.0 ± 0.2 | 6.6 ± 0.2 | 7.4 ± 0.2 | < 0.001 | 0.06 | 0.04 | 4.8 ± 0.2 | 5.6 ± 0.6 | 5.3 ± 0.3 | 0.58 | 0.46 | 0.93 |
| Grip strength (kgf) | 19.9 ± 1.1 | 29.4 ± 1.4 | 32.8 ± 1.3 | < 0.001 | < 0.001 | 0.28 | 10.3 ± 1.0 | 12.6 ± 2.6 | 20.6 ± 0.8 | < 0.001 | 0.55 | 0.02 |
| Serum AOPPs level (μM) | 114.7 ± 4.6 | 90.0 ± 5.1 | 85.0 ± 6.0 | 0.001 | 0.007 | 0.85 | 88.2 ± 5.2 | 81.1 ± 17.5 | 68.3 ± 9.6 | 0.38 | 0.88 | 0.74 |
| Oxidized albumin (%) (Cys‐albumin) | 55.0 ± 1.5 | 52.9 ± 1.4 | 49.8 ± 1.4 | 0.07 | 0.63 | 0.47 | 51.6 ± 1.7 | 51.3 ± 3.1 | 42.5 ± 1.4 | 0.02 | 1.00 | 0.15 |
AOPPs, advanced oxidation protein products.